Document is current
Any future updates will be listed below
-
Authors
Friederich, Marisa W.
Timal, Sharita
Powell, Christopher A.
Dallabona, Cristina
Kurolap, Alina https://orcid.org/0000-0002-7005-3621
Palacios-Zambrano, Sara
Bratkovic, Drago
Derks, Terry G. J.
Bick, David
Bouman, Katelijne
Chatfield, Kathryn C.
Damouny-Naoum, Nadine
Dishop, Megan K.
Falik-Zaccai, Tzipora C.
Fares, Fuad
Fedida, Ayalla
Ferrero, Ileana
Gallagher, Renata C.
Garesse, Rafael
Gilberti, Micol
González, Cristina
Gowan, Katherine
Habib, Clair
Halligan, Rebecca K.
Kalfon, Limor
Knight, Kaz
Lefeber, Dirk
Mamblona, Laura
Mandel, Hanna
Mory, Adi
Ottoson, John
Paperna, Tamar
Pruijn, Ger J. M.
Rebelo-Guiomar, Pedro F.
Saada, Ann
Sainz, Bruno Jr. https://orcid.org/0000-0003-4829-7651
Salvemini, Hayley
Schoots, Mirthe H.
Smeitink, Jan A. https://orcid.org/0000-0003-1392-8038
Szukszto, Maciej J. https://orcid.org/0000-0002-0463-652X
ter Horst, Hendrik J.
van den Brandt, Frans
van Spronsen, Francjan J.
Veltman, Joris A.
Wartchow, Eric
Wintjes, Liesbeth T.
Zohar, Yaniv
Fernández-Moreno, Miguel A.
Baris, Hagit N.
Donnini, Claudia
Minczuk, Michal
Rodenburg, Richard J. https://orcid.org/0000-0001-5227-3527
Van Hove, Johan L. K.
- License Information
-
More Information
Article History
Received: 9 February 2018
Accepted: 23 August 2018
First Online: 3 October 2018
Competing interests
: Dr. Smeitink is CEO of Khondrion, a mitochondrial medicine company. This study did not pose a conflict of interest. All other authors declare no real or apparent conflict of interest.
